Incannex Healthcare Updates Business Address in 8-K Filing

TL;DR

**Incannex Healthcare Inc. just changed its official business address, filed on January 17, 2024.**

AI Summary

Incannex Healthcare Inc. filed an 8-K on January 17, 2024, to update its business address from 401 Docklands Drive, Suite 15, Level 12, Docklands, Victoria 3008, Australia, to Suite 105, 8 Century Circuit, Norwest, NSW 2153, Australia. This change is important for investors because it ensures they have the most current contact information for the company, which is crucial for official communications and understanding the company's operational base.

Why It Matters

This filing provides updated contact information for Incannex Healthcare Inc., ensuring investors and regulators have the correct details for official correspondence and company operations.

Risk Assessment

Risk Level: low — Changing a business address is a routine administrative update and does not typically indicate significant operational or financial risk.

Analyst Insight

Investors should update their records with the new business address for Incannex Healthcare Inc. to ensure they receive any future physical correspondence and have accurate company information.

Key Numbers

• $0.0001 — par value per share (par value of Incannex Healthcare Inc. Common Stock)

Key Players & Entities

• Incannex Healthcare Inc. (company) — the registrant filing the 8-K
• January 17, 2024 (date) — date of the report
• 401 Docklands Drive, Suite 15, Level 12, Docklands, Victoria 3008, Australia (address) — former business address of Incannex Healthcare Inc.
• Suite 105, 8 Century Circuit, Norwest, NSW 2153, Australia (address) — new business address of Incannex Healthcare Inc.
• 001-41106 (number) — Commission File Number
• Delaware (location) — State of Incorporation for Incannex Healthcare Inc.
• IXHL (ticker) — Trading Symbol for Incannex Healthcare Inc. Common Stock
• The Nasdaq Stock Market LLC (exchange) — exchange where Incannex Healthcare Inc. Common Stock is registered

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IXHL The Nasdaq

Filing Documents

• ea191729-8k_incannex.htm (8-K) — 27KB
• ea191729ex99-1_incannex.htm (EX-99.1) — 21KB
• ex99-1_001.jpg (GRAPHIC) — 4KB
• 0001213900-24-003880.txt ( ) — 229KB
• ixhl-20240117.xsd (EX-101.SCH) — 3KB
• ixhl-20240117_lab.xml (EX-101.LAB) — 33KB
• ixhl-20240117_pre.xml (EX-101.PRE) — 22KB
• ea191729-8k_incannex_htm.xml (XML) — 3KB

01

Item 8.01 On January 17, 2024, Incannex Healthcare Inc. announced that it received approval from an Institutional Review Board with respect to its protocol to commence a Phase 2/3 clinical trial to assess the safety and efficacy of proprietary combination drug candidate IHL-42X in patients with obstructive sleep apnea. Further information is included in the press release attached as Exhibit 99.1 hereto, which is incorporated by reference into this Item 8.01.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Incannex Healthcare Inc., dated January 17, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Incannex Healthcare Inc. Date: January 17, 2024 /s/ Joel Latham Name: Joel Latham Title: Chief Executive Officer and President 2

View Full Filing

View this 8-K filing on SEC EDGAR